Navigation Links
Align Technology to Announce First Quarter Fiscal 2009 Results on April 23, 2009
Date:4/2/2009

SANTA CLARA, Calif. April 2 /PRNewswire-FirstCall/ -- Align Technology, Inc. (Nasdaq: ALGN), the inventor of Invisalign(R), announced today that the Company will report first quarter 2009 financial results on Thursday, April 23, 2009 after the close of market. Financial results will be released over PR Newswire and First Call and will be available on the Investor Relations section of the Company's website at http://investor.aligntech.com.

Following the press release, the Company will host a conference call to discuss its financial results. The conference call will begin at 4:30 p.m. ET (1:30 p.m. PT) and will also be available as an audio web cast live via the Internet. To access the web cast, please visit the Investor Relations section of Align Technology's website at http://investor.aligntech.com. To access the conference call, please dial 201-689-8341 approximately fifteen minutes prior to the start of the call.

If you are unable to listen to the call, an archived web cast will be available beginning approximately one hour after the call's conclusion and will remain available for approximately 12 months. Additionally, a telephonic replay of the call can be accessed by dialing 877-660-6853 with account number 292 followed by # and conference number 318996 followed by #. The replay must be accessed from international locations by dialing 201-612-7415 and using the same account and conference numbers referenced above. The telephonic replay will be available through 5:30 p.m. ET on May 06, 2009.

About Align Technology, Inc.

Align Technology designs, manufactures and markets Invisalign, a proprietary method for treating malocclusion, or the misalignment of teeth. Invisalign corrects maloc
'/>"/>

SOURCE Align Technology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. NovaLign(TM) Orthopaedics, Inc. Announces its First 510(K) Clearance From the FDA for New Intramedullary Fixation System
2. Poniard Pharmaceuticals to Focus Company Resources on Late-Stage Oncology Candidate Picoplatin Through Realignment of Research Organization
3. Dr. James F. Pingpank to Present at the Sixth International Symposium on Melanoma and Other Cutaneous Malignancies on March 13- 14, 2009 in New York City
4. A new measure for the malignancy of melanoma
5. Align Technology Names Sheila Tan as VP, Marketing and Chief Marketing Officer
6. Precyse Solutions Adds Executives, Realigns Around Service Lines
7. Align Technology Announces International Availability of Invisalign Teen(TM)
8. EMSI Realigns Internal Divisions for More Effective Focus on Customers
9. Video: The MDS Foundation Says Published Data Confirms VIDAZA(R) Significantly Extends Survival in Patients with the Malignant Condition MDS
10. Align Technology Asserts ClearCorrect Complaint Is Without Merit
11. Biomarker Combination and Risk of Ovarian Malignancy Algorithm (Roma(TM)) Demonstrates Accuracy in Detecting Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Shanghai, China (PRWEB) December 22, 2014 ... for MabThera (rituximab) for the treatment of non-Hodgkin’s lymphoma ... Health , a leading global healthcare consulting firm. MabThera ... B-cell lymphoma (DLBCL), the most common form of NHL. ... Market Access and Barriers,” the incidence of NHL in ...
(Date:12/22/2014)... Give a loved one the greatest ... health and vitality. , For a limited time, HealthiPlus ... formulas in special Holiday Wellness gift packages at drastically ... Each bottle contains cutting-edge, proven nutritional support for joints, ... well as we age. , Joint Health ...
(Date:12/22/2014)... Texas (PRWEB) December 22, 2014 7,178 ... and bustle of Black Friday shopping and opted instead ... and marketing education company, for their 5th annual “Black ... charged just $7 to attend the 5 hour ... that they promptly donated to support two Central Texas ...
(Date:12/22/2014)... December 22, 2014 NAPW ... Professional Woman of the Year. She is recognized with ... largest, most recognized networking organization of professional women in ... National Association of Professional Women is a vibrant networking ... Chapters. , Ms. Kreider is passionate and committed to ...
(Date:12/21/2014)... 2014 In this report, the ... power source, product, and application. The market, by ... pneumatic instruments. By product, the market covers the ... The handpieces market is further subdivided into drills, ... laparoscopic instruments, shavers, wire/pin drivers, and others. Moreover, ...
Breaking Medicine News(10 mins):Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 3Health News:National Association of Professional Women Announces Cheryl A. Kreider, President / CEO of Kreider Health Solutions, LLC, a 2014 Professional Woman of the Year 2Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 4
... Australian-based,natural health care products company that markets a range ... nature identical ingredients,announced today that its Quit Nits head ... United States through a distribution agreement with,CVS Pharmacies., ... agreement was the,result of two years of hard work ...
... identified a gene that is the key switch that ... , Much like students in a kindergarten class lining ... is identified as Smarcd3, must align correctly with two ... known as myogenesis, said principal investigator Monte Westerfield, a ...
... is a company with a renowned track record ... high throughput technologies. Genomatix algorithms include optimized fast ... complete genome annotation in terms of transcriptome and ... databases in this specific content by a factor ...
... of us probably don,t think much,about being regular, ... Johanson,practicing gastroenterologist at the Beloit Clinic in Beloit, ... health is that we,re,not getting enough fiber., ... http://media.medialink.com/WebNR.aspx?story=34435 Registered journalists can access video, ...
... the top killers in the country, but youd never know it ... of the Society for Critical Care Medicine (SCCM). , Research ... blood pressure, yet many of them dont even know it. ... the medications they need to control it," says Dr. Christopher Granger, ...
... improves access by ... care facilities and consumers, BUFFALO, N.Y., Jan. ... health care provider network to provide,routine wellness and ... the company announced today., HealthTransaction Network connects ...
Cached Medicine News:Health News:Wild Child's 'Quit Nits' Offers a Safe, Natural Alternative to Current Toxic Head Lice Products 2Health News:Wild Child's 'Quit Nits' Offers a Safe, Natural Alternative to Current Toxic Head Lice Products 3Health News:Oregon researchers find trigger gene for muscle development 2Health News:Severe hypertension: 'Silent killer' still on the loose 2Health News:Buffalo Company Launches First-ever National Electronic Transaction Network to Improve Health Care Access for Uninsured and Underinsured 2Health News:Buffalo Company Launches First-ever National Electronic Transaction Network to Improve Health Care Access for Uninsured and Underinsured 3
(Date:12/22/2014)... Cyberonics, Inc. (NASDAQ: CYBX ), a ... of epilepsy, today announced it will participate in the 33 ... 14, 2015, in San Francisco . ... Officer, will speak at 11:00 AM Pacific Time.  A live ... on the Investor Relations link on the Cyberonics home page ...
(Date:12/22/2014)... , Dec, 22, 2014  Eiger BioPharmaceuticals Incorporated ... study of lonafarnib in patients with chronic hepatitis ... at the National Institutes of Health (NIH) Clinical ...  The double-blinded, randomized, placebo-controlled, dose ascending study evaluated ... and 200 mg twice daily for 28 days.  ...
(Date:12/19/2014)... WAYNE, N.J. , Dec. 19, 2014  In the Friday, ... , a 16-page supplement dedicated to Healthcare Information Technology (HIT) features ... innovation in Healthcare IT in partnership with several leading healthcare organizations. ... be distributed across several major metropolitan markets, such as ... Washington DC / Baltimore , Minneapolis ...
Breaking Medicine Technology:Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3USA Today Supplement Featuring Konica Minolta Focuses on Impact of Healthcare IT 2
... published online in the journal Current Medical Research and ... type 2 diabetes treated with the fixed-dose combination ACTO plus ... reached the study goal of hemoglobin A1c (HbA1c) of less ... alone. Safety and tolerability of ACTO plus met therapy ...
... CHANGCHUN, China and LOS ANGELES, Oct. 14 /PRNewswire-Asia/ ... Yongxin,Pharmaceuticals" or "the Company"), a leading manufacturer, distributor and,retailer ... results for the second quarter of 2009 which ended ... the second quarter of 2009 were essentially flat at,approximately ...
Cached Medicine Technology:New Data Showed Type 2 Diabetes Patients Experienced Greater Blood Sugar Reductions when Treated with ACTOplus met(R) (pioglitazone HCl and metformin HCl) as Initial Therapy Compared to Either Component Alone 2New Data Showed Type 2 Diabetes Patients Experienced Greater Blood Sugar Reductions when Treated with ACTOplus met(R) (pioglitazone HCl and metformin HCl) as Initial Therapy Compared to Either Component Alone 3New Data Showed Type 2 Diabetes Patients Experienced Greater Blood Sugar Reductions when Treated with ACTOplus met(R) (pioglitazone HCl and metformin HCl) as Initial Therapy Compared to Either Component Alone 4New Data Showed Type 2 Diabetes Patients Experienced Greater Blood Sugar Reductions when Treated with ACTOplus met(R) (pioglitazone HCl and metformin HCl) as Initial Therapy Compared to Either Component Alone 5New Data Showed Type 2 Diabetes Patients Experienced Greater Blood Sugar Reductions when Treated with ACTOplus met(R) (pioglitazone HCl and metformin HCl) as Initial Therapy Compared to Either Component Alone 6China Yongxin Pharmaceuticals Inc. Announces Second Quarter 2009 Financial Results 2China Yongxin Pharmaceuticals Inc. Announces Second Quarter 2009 Financial Results 3China Yongxin Pharmaceuticals Inc. Announces Second Quarter 2009 Financial Results 4China Yongxin Pharmaceuticals Inc. Announces Second Quarter 2009 Financial Results 5China Yongxin Pharmaceuticals Inc. Announces Second Quarter 2009 Financial Results 6China Yongxin Pharmaceuticals Inc. Announces Second Quarter 2009 Financial Results 7China Yongxin Pharmaceuticals Inc. Announces Second Quarter 2009 Financial Results 8China Yongxin Pharmaceuticals Inc. Announces Second Quarter 2009 Financial Results 9China Yongxin Pharmaceuticals Inc. Announces Second Quarter 2009 Financial Results 10China Yongxin Pharmaceuticals Inc. Announces Second Quarter 2009 Financial Results 11
... The AFX Lens is ... for use in an air-filled ... use as a primary air-fluid ... profile and sutureless design make ...
... 45° Prism is designed ... and are recommended for ... BRVO etc.) and Rhegmatogenus ... be used for panretinal ...
... Chalam Flat is designed for ... and induction of posterior vitreous ... for macula whole surgery, epiretinal ... tractional epiretinal membranes. Direct image ...
... magnification and increased stereopsis, the Central Retinal ... to the equatorial regions. The Central Retinal ... in membrane peeling in proliferative vitreoretinopathy extending ... The ACS Vitrectomy Lenses from Volk can ...
Medicine Products: